Welcome to GEN’s COVID-19 DRUG & VACCINE CANDIDATE TRACKER website.
Updated: March 5, 2020
Total Drug & Vaccine Candidates: 304 (as of March 5)
The goal of this resource is to provide a comprehensive collection of news, milestones, and updates on drug and vaccine candidates currently being developed for the COVID-19 pandemic.
This resource is based on the reporting of GEN senior news editor Alex Philippidis, who began compiling information on drug and vaccine candidates in the early weeks of the pandemic. The numbers of verified candidates ballooned rapidly from 35 in February 2020, to 60 in March, to 160 in April.
Since then, more than a half dozen COVID-19 vaccines and additional drugs have received at least emergency authorization, if not full approval. Biopharmas, regulators, and academic researchers have ramped up efforts to develop and evaluate COVID-19 drug and vaccine candidates designed to vanquish the virus.
“Fortunately now, we have a dramatic diminution going down, but we can’t be complacent about that because there are variants, namely mutations, that could in fact turn it around again,” Anthony Fauci, MD, Director of the NIH’s National Institute of Allergy and Infectious Diseases (NIAID), said February 18 at a virtual community conversation held by The College of William & Mary.
The number of legitimate COVID-19 candidates is approximately divided between vaccines and drugs, with approximately 4,200 clinical trials for COVID-19 therapeutics either initiated, recruiting (openly or via invitation), or active but not recruiting participants, according to ClinicalTrials.gov.
To help navigate through the potential therapeutic options for COVID-19, GEN had divided this list of candidates into four broad categories based on their developmental and (where applicable) clinical progress:
● FRONT RUNNER – the most validated or touted therapeutics in development, based on advanced stages of activity, favorable data or both.
● DEFINITELY MAYBE – candidates in earlier phases with the most promising partners, or more advanced candidates well under way in development that have generated uneven data.
● KEEPING AN EYE ON… – interesting technology, attracting notable partners, or both, but still early days.
● TOO SOON TO TELL – longshots or new entries pending additional details from their developers and/or clinical progress.
GEN categorizes the most common treatment categories by color, including antibodies, antivirals, RNA-based treatments, and vaccines. Please click any category to see the full list of candidates and information on each therapy/vaccine.
To accelerate development of vaccines and drugs, the NIH has launched Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV), a public-private effort through which U.S. regulators, the European Medicines Agency, and more than a dozen biopharma giants are prioritizing and accelerating clinical study of drug and vaccine candidates deemed to have short-term potential for success.
GEN will update the COVID-19 tracker as frequently as possible. Comments and suggestions are welcome: aphilippidis at genengnews dot com.